Literature DB >> 19141600

Endocrine-immune-paracrine interactions in prostate cells as targeted by phytomedicines.

Nora E Gray1, Xunxian Liu, Renee Choi, Marc R Blackman, Julia T Arnold.   

Abstract

Dehydroepiandrosterone (DHEA) is used as a dietary supplement and can be metabolized to androgens and/or estrogens in the prostate. We investigated the hypothesis that DHEA metabolism may be increased in a reactive prostate stroma environment in the presence of proinflammatory cytokines such as transforming growth factor beta1 (TGFbeta1), and further, whether red clover extract, which contains a variety of compounds including isoflavones, can reverse this effect. LAPC-4 prostate cancer cells were grown in coculture with prostate stromal cells (6S) and treated with DHEA +/- TGFbeta1 or interleukin-6. Prostate-specific antigen (PSA) expression and testosterone secretion in LAPC-4/6S cocultures were compared with those in monocultured epithelial and stromal cells by real-time PCR and/or ELISA. Combined administration of TGFbeta1 + DHEA to cocultures increased PSA protein secretion two to four times, and PSA gene expression up to 50-fold. DHEA + TGFbeta1 also increased coculture production of testosterone over DHEA treatment alone. Red clover isoflavone treatment led to a dose-dependent decrease in PSA protein and gene expression and testosterone metabolism induced by TGFbeta1 + DHEA in prostate LAPC-4/6S cocultures. In this coculture model of endocrine-immune-paracrine interactions in the prostate, TGFbeta1 greatly increased stromal-mediated DHEA effects on testosterone production and epithelial cell PSA production, whereas red clover isoflavones reversed these effects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19141600      PMCID: PMC2757651          DOI: 10.1158/1940-6207.CAPR-08-0062

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  37 in total

1.  Phytoestrogens inhibit human 17beta-hydroxysteroid dehydrogenase type 5.

Authors:  A Krazeisen; R Breitling; G Möller; J Adamski
Journal:  Mol Cell Endocrinol       Date:  2001-01-22       Impact factor: 4.102

2.  Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis.

Authors:  A M De Marzo; V L Marchi; J I Epstein; W G Nelson
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 3.  Does DHEA exert direct effects on androgen and estrogen receptors, and does it promote or prevent prostate cancer?

Authors:  Julia T Arnold; Marc R Blackman
Journal:  Endocrinology       Date:  2005-11       Impact factor: 4.736

4.  From transforming growth factor-beta signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells.

Authors:  H Y Kang; H K Lin; Y C Hu; S Yeh; K E Huang; C Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

5.  Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression.

Authors:  D L Lin; M C Whitney; Z Yao; E T Keller
Journal:  Clin Cancer Res       Date:  2001-06       Impact factor: 12.531

6.  Long-term pharmacokinetics of an extract of isoflavones from red clover (Trifolium pratense).

Authors:  Jan Howes; Mark Waring; Li Huang; Laurence G Howes
Journal:  J Altern Complement Med       Date:  2002-04       Impact factor: 2.579

Review 7.  Reactive stroma in prostate cancer progression.

Authors:  J A Tuxhorn; G E Ayala; D R Rowley
Journal:  J Urol       Date:  2001-12       Impact factor: 7.450

Review 8.  DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology.

Authors:  F Labrie; V Luu-The; C Labrie; J Simard
Journal:  Front Neuroendocrinol       Date:  2001-07       Impact factor: 8.606

Review 9.  Role of transforming growth factor-beta1 in prostate cancer.

Authors:  P Wikström; J Damber; A Bergh
Journal:  Microsc Res Tech       Date:  2001-02-15       Impact factor: 2.769

Review 10.  Crucial role of cytokines in sex steroid formation in normal and tumoral tissues.

Authors:  J Simard; S Gingras
Journal:  Mol Cell Endocrinol       Date:  2001-01-22       Impact factor: 4.102

View more
  6 in total

1.  Dehydroepiandrosterone administration or G{alpha}q overexpression induces {beta}-catenin/T-Cell factor signaling and growth via increasing association of estrogen receptor-{beta}/Dishevelled2 in androgen-independent prostate cancer cells.

Authors:  Xunxian Liu; Julia T Arnold; Marc R Blackman
Journal:  Endocrinology       Date:  2010-02-22       Impact factor: 4.736

2.  Androgen-induced PSA expression requires not only activation of AR but also endogenous IGF-I or IGF-I/PI3K/Akt signaling in human prostate cancer epithelial cells.

Authors:  Xunxian Liu; Renee Y Choi; Shayma M Jawad; Julia T Arnold
Journal:  Prostate       Date:  2010-10-28       Impact factor: 4.104

3.  The EPI bioassay identifies natural compounds with estrogenic activity that are potent inhibitors of androgenic pathways in human prostate stromal and epithelial cells.

Authors:  Günter Vollmer; Janina Helle; Hakima Amri; Xunxian Liu; Julia T Arnold
Journal:  J Steroid Biochem Mol Biol       Date:  2011-12-22       Impact factor: 4.292

4.  Transforming growth factor β1 increase of hydroxysteroid dehydrogenase proteins is partly suppressed by red clover isoflavones in human primary prostate cancer-derived stromal cells.

Authors:  Xunxian Liu; Yun-Shang Piao; Julia T Arnold
Journal:  Carcinogenesis       Date:  2011-09-12       Impact factor: 4.944

5.  TGFβ1 alters androgenic metabolites and hydroxysteroid dehydrogenase enzyme expression in human prostate reactive stromal primary cells: Is steroid metabolism altered by prostate reactive stromal microenvironment?

Authors:  Yun-shang Piao; Paddy Wiesenfeld; Robert Sprando; Julia T Arnold
Journal:  J Steroid Biochem Mol Biol       Date:  2013-06-13       Impact factor: 4.292

Review 6.  DHEA metabolism in prostate: For better or worse?

Authors:  Julia T Arnold
Journal:  Mol Cell Endocrinol       Date:  2008-11-01       Impact factor: 4.102

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.